Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, TN, 37203, USA.
Curr Oncol Rep. 2012 Oct;14(5):411-8. doi: 10.1007/s11912-012-0254-8.
B-cell receptor signaling plays varied and critical roles in B-cell development, homeostasis and disease. The key players of the pathway and its many signaling modulators have been identified as well as some of the mechanisms by which the pathway is regulated. With the increased incidence of non-Hodgkin's lymphoma in recent years, there is a clear clinical need for novel agents to offer new options in resistant disease to potentially improve outcomes in curative settings. With the tremendous insight gained in the last 2 decades from basic science research, our understanding of the pathobiology of the B-cell receptor is leading to the discovery and clinical development of many new therapeutic targets such as Syk, Bruton's tyrosine kinase, and phosphatidylinositol 3-kinase. This review will emphasize contemporary and salient findings on novel agents targeting the B-cell receptor signaling pathway for the treatment of non-Hodgkin's lymphoma.
B 细胞受体信号在 B 细胞发育、稳态和疾病中发挥着多样化和关键的作用。该途径的关键参与者及其许多信号调节剂以及该途径被调节的一些机制已经被确定。近年来,非霍奇金淋巴瘤的发病率不断增加,因此临床上显然需要新型药物来为耐药疾病提供新的选择,从而有可能改善治愈性环境中的结局。在过去 20 年中,基础科学研究取得了巨大的进展,使我们对 B 细胞受体的病理生物学有了更深入的了解,从而发现并正在临床开发许多新的治疗靶点,如 Syk、布鲁顿酪氨酸激酶和磷脂酰肌醇 3-激酶。本文将重点介绍针对 B 细胞受体信号通路的新型药物治疗非霍奇金淋巴瘤的最新研究进展。